PPARδ activation acts cooperatively with 3-phosphoinositide-dependent protein kinase-1 to enhance mammary tumorigenesis

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Pollock, Claire B ^a   Yin, Yuzhi ^a   Yuan, Hongyan ^a   Zeng, Xiao ^a   King, Sruthi ^b   Li, Xin ^b   Kopelovich, Levy ^c   Albanese, Chris ^a   Glazer, Robert I ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; FATTY ACID; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOLIPID; PROTEIN KINASE C ALPHA; S6 KINASE; 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE; 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER GROWTH; CONTROLLED STUDY; DIET THERAPY; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION PROFILING; GENETIC SIGNATURE; METABOLOMICS; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSGENE; TRANSGENIC MOUSE; ANIMAL; CELL TRANSFORMATION; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALIA; MOUSE MAMMARY TUMOR VIRUS; MUS; MUS MUSCULUS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; ENERGY METABOLISM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY NEOPLASMS, ANIMAL; METABOLOMICS; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PPAR DELTA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 79251588105     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016215     Document Type: Article

References (62)

1. Pearce LR, Komander D, Alessi DR (2010) The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 11: 9-22.
2. Yang KJ, Shin S, Piao L, Shin E, Li Y, et al. (2008) Regulation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) by Src involves tyrosine phosphorylation of PDK1 and Src homology 2 domain binding. J Biol Chem 283: 1480-1491.
3. Riojas RA, Kikani CK, Wang C, Mao X, Zhou L, et al. (2006) Fine tuning PDK1 activity by phosphorylation at Ser163. J Biol Chem 281: 21588-21593.
4. Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, et al. (1997) 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 7: 776-789.
5. Casamayor A, Morrice NA, Alessi DR (1999) Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem J 342 (Pt 2): 287-292.
6. Kikani CK, Dong LQ, Liu F (2005) ''New''-clear functions of PDK1: beyond a master kinase in the cytosol? J Cell Biochem 96: 1157-1162.
7. Tian X, Rusanescu G, Hou W, Schaffhausen B, Feig LA (2002) PDK1 mediates growth factor-induced Ral-GEF activation by a kinase-independent mechanism. Embo J 21: 1327-1338.
8. Lee KY, D'Acquisto F, Hayden MS, Shim JH, Ghosh S (2005) PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation. Science 308: 114-118.
9. Yin Y, Yuan H, Wang C, Pattabiraman N, Rao M, et al. (2006) 3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation. Mol Endocrinol 20: 268-278.
10. Lawlor MA, Mora A, Ashby PR, Williams MR, Murray-Tait V, et al. (2002) Essential role of PDK1 in regulating cell size and development in mice. Embo J 21: 3728-3738.
11. Mora A, Davies AM, Bertrand L, Sharif I, Budas GR, et al. (2003) Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. Embo J 22: 4666-4676.
12. Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, et al. (2009) 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res 69: 6299-6306.
13. Xie Z, Yuan H, Yin Y, Zeng X, Bai R, et al. (2006) 3-phosphoinositidedependent protein kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases. BMC Cancer 6: 77.
14. Lin HJ, Hsieh FC, Song H, Lin J (2005) Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer 93: 1372-1381.
15. Xie Z, Zeng X, Waldman T, Glazer RI (2003) Transformation of mammary epithelial cells by 3-phosphoinositide- dependent protein kinase-1 activates betacatenin and c-Myc, and down-regulates caveolin-1. Cancer Res 63: 5370-5375.
16. Liu Y, Wang J, Wu M, Wan W, Sun R, et al. (2009) Down-regulation of 3-phosphoinositide-dependent protein kinase-1 levels inhibits migration and experimental metastasis of human breast cancer cells. Mol Cancer Res 7: 944-954.
17. Zeng X, Xu H, Glazer RI (2002) Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha. Cancer Res 62: 3538-3543.
18. Liang K, Lu Y, Li X, Zeng X, Glazer RI, et al. (2006) Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol 70: 1045-1052.
19. Berger JP, Akiyama TE, Meinke PT (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26: 244-251.
20. Stephen RL, Gustafsson MC, Jarvis M, Tatoud R, Marshall BR, et al. (2004) Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res 64: 3162-3170.
21. Glazer RI, Yuan H, Xie Z, Yin Y (2008) PPARgamma and PPARdelta as Modulators of Neoplasia and Cell Fate. PPAR Res 2008: 247379.
22. Koeffler HP (2003) Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 9: 1-9.
23. Knutsen HK, Olstorn HB, Paulsen JE, Husoy T, Goverud IL, et al. (2005) Increased levels of PPARbeta/delta and cyclin D1 in flat dysplastic ACF and adenomas in Apc(Min/+) mice. Anticancer Res 25: 3781-3789.
24. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, et al. (2004) Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 10: 245-247.
25. Jaeckel EC, Raja S, Tan J, Das SK, Dey SK, et al. (2001) Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 127: 1253-1259.
26. Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA, et al. (2000) Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptordelta in human endometrial adenocarcinoma. Neoplasia 2: 483-490.
27. Suchanek KM, May FJ, Lee WJ, Holman NA, Roberts-Thomson SJ (2002) Peroxisome proliferator-activated receptor beta expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin. Int J Biochem Cell Biol 34: 1051-1058.
28. Pedchenko TV, Gonzalez AL, Wang D, Dubois RN, Massion PP (2008) Peroxisome Proliferator-Activated Receptor {beta}/{delta} Expression and Activation in Lung Cancer. Am J Respir Cell Mol Biol.
29. Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, et al. (2005) Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 65: 3950-3957.
30. Pollock CB, Rodriguez O, Martin PL, Albanese C, Li X, et al. (2010) Induction of metastatic gastric cancer by peroxisome prolferator-activated receptor-delta activation. PPAR Res, in press.
31. Ghosh M, Ai Y, Narko K, Wang Z, Peters JM, et al. (2009) PPAR delta is protumorigenic in a mouse model of COX-2-induced mammary cancer. Prostaglandins Other Lipid Mediat 88: 97-100.
32. Park BH, Vogelstein B, Kinzler KW (2001) Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci U S A 98: 2598-2603.
33. Barak Y, Liao D, He W, Ong ES, Nelson MC, et al. (2002) Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A 99: 303-308.
34. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, et al. (2004) Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med 10: 481-483.
35. Di-Poi N, Michalik L, Tan NS, Desvergne B, Wahli W (2003) The antiapoptotic role of PPARbeta contributes to efficient skin wound healing. J Steroid Biochem Mol Biol 85: 257-265.
36. Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B (2002) Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 10: 721-733.
37. Han S, Ritzenthaler JD, Sun X, Zheng Y, Roman J (2009) Activation of peroxisome proliferator-activated receptor beta/delta induces lung cancer growth via peroxisome proliferator-activated receptor coactivator gamma-1alpha. Am J Respir Cell Mol Biol 40: 325-331.
38. Wang D, Wang H, Guo Y, Ning W, Katkuri S, et al. (2006) Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A 103: 19069-19074.
39. Yin Y, Yuan H, Zeng X, Kopelovich L, Glazer RI (2009) Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptordependent tumor specification. Cancer Res 69: 687-694.
40. Yin Y, Bai R, Russell RG, Beildeck ME, Xie Z, et al. (2005) Characterization of medroxyprogesterone and DMBA-induced multilineage mammary tumors by gene expression profiling. Mol Carcinog 44: 42-50.
41. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, et al. (2000) The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 19: 968-988.
42. Patterson AD, Li H, Eichler GS, Krausz KW, Weinstein JN, et al. (2008) UPLCESI-TOFMS-based metabolomics and gene expression dynamics inspector selforganizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem 80: 665-674.
43. Zeng X, Xu H, Park B-K, Glazer RI (2002) Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Ca. Cancer Res 62: 3538-3543.
44. Williams MR, Arthur JS, Balendran A, van der Kaay J, Poli V, et al. (2000) The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr Biol 10: 439-448.
45. Altenberg B, Greulich KO (2004) Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84: 1014-1020.
46. DeBerardinis RJ (2008) Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genet Med 10: 767-777.
47. Kramer DK, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, et al. (2007) Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem 282: 19313-19320.
48. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, et al. (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899.
49. Schmidt M, Voelker HU, Kapp M, Krockenberger M, Dietl J, et al. (2009) Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK. J Cancer Res Clin Oncol.
50. Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, et al. (2008) ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res 68: 8547-8554.
51. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB (2005) ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24: 6314-6322.
52. Abbot EL, McCormack JG, Reynet C, Hassall DG, Buchan KW, et al. (2005) Diverging regulation of pyruvate dehydrogenase kinase isoform gene expression in cultured human muscle cells. Febs J 272: 3004-3014.
53. Sedlakova I, Vavrova J, Tosner J, Hanousek L (2008) Lysophosphatidic acid: an ovarian cancer marker. Eur J Gynaecol Oncol 29: 511-514.
54. Bayascas JR, Leslie NR, Parsons R, Fleming S, Alessi DR (2005) Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/2) mice. Curr Biol 15: 1839-1846.
55. Shao J, Sheng H, DuBois RN (2002) Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 62: 3282-3288.
56. Sato S, Fujita N, Tsuruo T (2004) Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway. J Biol Chem 279: 33759-33767.
57. He TC, Chan TA, Vogelstein B, Kinzler KW (1999) PPARdelta is an APCregulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-345.
58. Genini D, Catapano CV (2007) Block of nuclear receptor ubiquitination. A mechanism of ligand-dependent control of peroxisome proliferator-activated receptor delta activity. J Biol Chem 282: 11776-11785.
59. Forman BM, Chen J, Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94: 4312-4317.
60. Behbod F, Xian W, Shaw CA, Hilsenbeck SG, Tsimelzon A, et al. (2006) Transcriptional profiling of mammary gland side population cells. Stem Cells 24: 1065-1074.
61. Li Y, Chen B, Chen J, Lou G, Chen S, et al. (2008) Fast skeletal muscle troponin I is a co-activator of estrogen receptor-related receptor alpha. Biochem Biophys Res Commun 369: 1034-1040.
62. Giguere V (2008) Transcriptional control of energy homeostasis by the estrogenrelated receptors. Endocr Rev 29: 677-696.